BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 32673688)

  • 1. Analysis of IL-6 serum levels and CAR T cell-specific digital PCR in the context of cytokine release syndrome.
    Pabst T; Joncourt R; Shumilov E; Heini A; Wiedemann G; Legros M; Seipel K; Schild C; Jalowiec K; Mansouri Taleghani B; Fux M; Novak U; Porret N; Zeerleder S; Bacher U
    Exp Hematol; 2020 Aug; 88():7-14.e3. PubMed ID: 32673688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma Exchange Can Be an Alternative Therapeutic Modality for Severe Cytokine Release Syndrome after Chimeric Antigen Receptor-T Cell Infusion: A Case Report.
    Xiao X; He X; Li Q; Zhang H; Meng J; Jiang Y; Deng Q; Zhao M
    Clin Cancer Res; 2019 Jan; 25(1):29-34. PubMed ID: 30322878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.
    Yan Z; Zhang H; Cao J; Zhang C; Liu H; Huang H; Cheng H; Qiao J; Wang Y; Wang Y; Gao L; Shi M; Sang W; Zhu F; Li D; Sun H; Wu Q; Qi Y; Li H; Wang X; Li Z; Liu H; Zheng J; Qian W; Zhang X; Xu K
    Front Immunol; 2021; 12():611366. PubMed ID: 33708205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome.
    Kotch C; Barrett D; Teachey DT
    Expert Rev Clin Immunol; 2019 Aug; 15(8):813-822. PubMed ID: 31219357
    [No Abstract]   [Full Text] [Related]  

  • 5. Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia.
    Li J; Wu Z; Zhao N
    Adv Ther; 2019 Oct; 36(10):2881-2894. PubMed ID: 31428935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T).
    Alvi RM; Frigault MJ; Fradley MG; Jain MD; Mahmood SS; Awadalla M; Lee DH; Zlotoff DA; Zhang L; Drobni ZD; Hassan MZO; Bassily E; Rhea I; Ismail-Khan R; Mulligan CP; Banerji D; Lazaryan A; Shah BD; Rokicki A; Raje N; Chavez JC; Abramson J; Locke FL; Neilan TG
    J Am Coll Cardiol; 2019 Dec; 74(25):3099-3108. PubMed ID: 31856966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [CARs, CRS and neurotoxicity: severe complications after administration of immunotherapy : Essentials for intensivists].
    Prinz J; d'Hargues Y; Gödel P; Shimabukuro-Vornhagen A; Kochanek M; Böll B
    Med Klin Intensivmed Notfmed; 2020 Apr; 115(3):198-204. PubMed ID: 30547223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Establishment of a cytokine release syndrome associated with chimeric antigen receptor T cell treatment in SCID/Beige mice model].
    Shan JQ; Nan SF; Li F; Shen CY; Zhang Y
    Zhonghua Zhong Liu Za Zhi; 2021 Dec; 43(12):1248-1254. PubMed ID: 34915632
    [No Abstract]   [Full Text] [Related]  

  • 9. The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review.
    Jin Z; Xiang R; Qing K; Li X; Zhang Y; Wang L; Zhu H; Mao Y; Xu Z; Li J
    Ann Hematol; 2018 Aug; 97(8):1327-1335. PubMed ID: 29766234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Significance of Cytokine Release Syndrome in B Cell Hematological Malignancies Patients After Chimeric Antigen Receptor T Cell Therapy.
    Dong R; Jiang S; Chen Y; Ma Y; Sun L; Xing C; Zhang S; Yu K
    J Interferon Cytokine Res; 2021 Dec; 41(12):469-476. PubMed ID: 34935483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A distinct cytokine network distinguishes chimeric antigen receptor T cell (CAR-T)-associated hemophagocytic lymphohistiocytosis-like toxicity (carHLH) from severe cytokine release syndrome following CAR-T therapy.
    Zu C; Wu S; Zhang M; Wei G; Xu H; Cui J; Chang AH; Huang H; Hu Y
    Cytotherapy; 2023 Nov; 25(11):1167-1175. PubMed ID: 37480884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case Report: Local Cytokine Release Syndrome in an Acute Lymphoblastic Leukemia Patient After Treatment With Chimeric Antigen Receptor T-Cell Therapy: A Possible Model, Literature Review and Perspective.
    Luan C; Zhou J; Wang H; Ma X; Long Z; Cheng X; Chen X; Huang Z; Zhang D; Xia R; Ge J
    Front Immunol; 2021; 12():707191. PubMed ID: 34349766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine release syndrome was an independent risk factor associated with hypoalbuminemia for patients with relapsed/refractory hematological malignancies after CAR-T cell therapy.
    Ding S; Chen R; Wang L; Zu C; Zhou X; Zhang J; Zhang M; Jin A; Wang T; Hu Y
    BMC Cancer; 2023 Nov; 23(1):1055. PubMed ID: 37919691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokine Release Syndrome after Treatment of Anti-CD19 CAR-T Therapy with IL-6 Knocking Down in Patients with Central Nervous System B-cell Acute Lymphocytic Leukemia.
    Mao Y; Xu X
    Ann Clin Lab Sci; 2021 Nov; 51(6):790-794. PubMed ID: 34921032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of cytokine release syndrome related to CAR-T cell therapy.
    Chen H; Wang F; Zhang P; Zhang Y; Chen Y; Fan X; Cao X; Liu J; Yang Y; Wang B; Lei B; Gu L; Bai J; Wei L; Zhang R; Zhuang Q; Zhang W; Zhao W; He A
    Front Med; 2019 Oct; 13(5):610-617. PubMed ID: 31571160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
    Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
    Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine release syndrome: grading, modeling, and new therapy.
    Liu D; Zhao J
    J Hematol Oncol; 2018 Sep; 11(1):121. PubMed ID: 30249264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Timing of Tocilizumab Administration Under the Guidance of IL-6 in CAR-T Therapy for R/R Acute Lymphoblastic Leukemia.
    Zhang Y; Zhou F; Wu Z; Li Y; Li C; Du M; Luo W; Kou H; Lu C; Mei H
    Front Immunol; 2022; 13():914959. PubMed ID: 35799791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies.
    Dos Santos DMC; Rejeski K; Winkelmann M; Liu L; Trinkner P; Günther S; Bücklein VL; Blumenberg V; Schmidt C; Kunz WG; Von Bergwelt-Baildon M; Theurich S; Subklewe M
    Haematologica; 2022 Sep; 107(9):2096-2107. PubMed ID: 35172565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis of Related Early Warning Indexes of Cytokine Release Syndrome in Multiple Myeloma Patients after CAR-T Treatment].
    Ye CY; Zhao LN; Wang SY; Cheng H; Chen W; Qi KM; Wu QY; Li ZY; Xu KL; Cao J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1203-1208. PubMed ID: 34362503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.